Drug profile · INN
rilpivirine hydrochloride
RILPIVIRINE HYDROCHLORIDE
rilpivirine hydrochloride (RILPIVIRINE HYDROCHLORIDE) is a human immunodeficiency virus type 1 reverse transcriptase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — rilpivirine hydrochloride
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 1
- Data quality
- 0.84
Quick answer
rilpivirine hydrochloride (RILPIVIRINE HYDROCHLORIDE) is a human immunodeficiency virus type 1 reverse transcriptase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Human immunodeficiency virus type 1 reverse transcriptase inhibitor
Primary target: Human immunodeficiency virus type 1 reverse transcriptase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is rilpivirine hydrochloride?
rilpivirine hydrochloride (RILPIVIRINE HYDROCHLORIDE) is a human immunodeficiency virus type 1 reverse transcriptase inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for rilpivirine hydrochloride?
RILPIVIRINE HYDROCHLORIDE is a marketed brand name for rilpivirine hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of rilpivirine hydrochloride?
rilpivirine hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.